WASHINGTON--(BUSINESS WIRE)--AHF, the world’s largest provider of HIV/AIDS care globally, calls on world and public health leaders to apply lessons learned from HIV/AIDS—‘the other pandemic’—to the ...

A recent study published in Communications Medicine discussed how experiences from the coronavirus disease 2019 (COVID-19) pandemic could be leveraged for human immunodeficiency virus (HIV). Study: ...

In 2020, global health has gone from a fringe issue to the forefront of people’s mind, all thanks to COVID-19. The last time the entire world came close to being as focused on a pandemic threat was ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

As the United States continues to confront the myriad challenges of the COVID-19 pandemic, I’ve been reflecting on the parallels between this public health crisis and the one that defined my formative ...

Three lessons learned from the human immunodeficiency virus (HIV) pandemic were published by an international group of public health researchers in April 2020 in response to the coronavirus disease ...

$7.5 million to Battle HIV/AIDS in the United States Earlier this month, President Barack Obama set out a new domestic AIDS policy, which asked cities, states, federal agencies, and the private sector ...

Abner Mason, CEO and founder of ConsejoSano, highlights how lessons learned from his early days in the fight against HIV and AIDS in Africa can inform improvements in health equity, especially in ...

Federal officials have a favorite refrain about COVID-19: "We have the tools." There's just one problem: As those who have worked to end HIV for decades know, just having the tools is not enough.

Infectious disease expert Dave Wessner reports from the 24 th International AIDS Conference, where researchers shared ways that Covid vaccine development might help the development of a vaccine for ...

The successful results from a clinical trial of a new, long-acting HIV prevention drug are not just a critical milestone for those working on HIV/AIDS, but also for researchers working on other deadly ...